A sticky situation
Pharmaceutical companies cannot survive just by developing ever more expensive drugs, health policy analyst Roy Lilley tells Peter Mansell, and says the industry must adapt to NHS change

Onwards and upwards for medicines access?
Don’t underestimate the importance of the government and industry’s latest report into collaborative working with the NHS, finds Lynne Taylor, as it seeks to make the best use of cost-effective medicines

Getting your message across
Are marketing and brand strategies making the most of health economics to leverage competitive advantage?

Treading new ground
Simon Friend, Global Pharmaceutical Leader at PricewaterhouseCoopers, outlines the changes in Japan’s pharmaceutical market that are heralding
opportunities for foreign companies.

Sweetening the pill
Becky McCall unpicks the new European Directive aimed at improving medicines for children, and
considers the impact for pharma

Let’s get clinical
Last month’s PharmaTimes Clinical Researcher of the Year 2006 awards ceremony saw the gathering of an elite group from the global clinical arena, all hoping for a taste of victory in a competition designed to recognise the best in the field

Emerging from the shadows
Can ghost-writing regain its reputation?